ClinicalTrials.gg
CompletedNCT03749642Updated May 27, 2021

Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy

A Phase 2 interventional study of trazodone/gabapentin 2.5/25 mg and trazodone/gabapentin 5/50 mg in Painful Diabetic Neuropathy, sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A. Completed at 30 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-05-27.

Sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Diabetic Neuropathies with a site in Poland — none open to participants now, none under way, none of them phase 3. Diabetic Neuropathies · Poland.

Enrollment
3rd of 10
240 · median 148
Started
2018
with 2 others
Phase 2
7 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
2 of 11
Aziende Chimiche Riunite Angelini Francesco S.p.A

Among the 11 studies in Diabetic Neuropathies with a site in Poland, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2018, is one of 7 in phase 2, and was the 9th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

None of the 11 studies in Diabetic Neuropathies with a site in Poland is open now. The open studies under Diabetic Neuropathies, anywhere →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Diabetic Neuropathies with a site in Poland as a file.
02

Study summary

The primary objective of the study is to collect preliminary information on the effect of three doses of trazodone/gabapentin FDC products on pain intensity in patients with painful diabetic neuropathy after 8-week treatment period.

Read the detailed description

The present phase II study is designed to collect preliminary data on the efficacy and safety of trazodone/gabapentin Fixed-Dose Combination (FDC)products for treatment of patients affected by painful diabetic neuropathy in a randomized controlled clinical trial. Diabetic peripheral neuropathic pain represents an important therapeutic challenge as its pathophysiology is not yet fully understood and pain relief is still unsatisfactory. The pharmacological treatments, with exception to those targeted to the glycemic control, are symptomatic and their use is limited by not universal efficacy, side effects or by the development of tolerance. A wide variety of drugs, used both alone and in combination, has shown to significantly reduce neuropathic pain when compared with placebo in randomized controlled trials, even though pain relief remains inadequate for most of the patients.

In this contest, Angelini S.p.A is developing a fixed-dose combination medicinal product for the treatment of neuropathic pain containing low doses of active ingredients: trazodone, a widely used antidepressant drug, and gabapentin which is indicated for the treatment of neuropathic pain.

03

Conditions studied

  • Painful Diabetic Neuropathy

Keywords

  • Trazodone
  • Gabapentin
  • Neuropathic pain
  • Placebo
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patient of any ethnic origin between 18 and 75 years of age (limits included).
  2. Neuropathic pain at feet/legs confirmed by Douleur Neuropatique 4 (DN4) score ≥ 4 at Screening Visit.
  3. Patient with bilateral distal symmetrical polyneuropathy confirmed by Toronto Clinical Neuropathy Scoring System (TCNSS) score > 5 at Screening visit.
  4. Pain persisting or taking pain medication for neuropathic pain for at least 3 months.
  5. Diabetic patient (type 1 or 2 diabetes mellitus) with value of ≤ 11% at Screening Visit and stable antidiabetic medication regimen for ≥30 days.
  6. Patient who is currently not receiving treatment for diabetic neuropathic pain or patient who is receiving treatment, with drug/s other than gabapentin, and has completed the required .
  7. Average daily pain score ≥ 4 based on the 11-point Numeric Rating Scale (NRS) at Visit 0, calculated from a minimum of four pain ratings in daily electronic device entries during the baseline period.
  8. Women of must have a negative pregnancy test at Screening Visit and have to agree not to start a pregnancy from the signature of the up to thirty days after the last administration of the product, using an appropriate method, such as combined estrogen and progestogen containing hormonal contraception (e.g. oral, intravaginal, transdermal), progestogen-only hormonal contraception (e.g. oral, injectable, implantable), intrauterine device (IUD) or intrauterine hormone-releasing system (IUS) in combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual abstinence.
  9. Legally capable to give their consent to participate in the study (including personal data processing) and available to sign and date the written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Known to trazodone or gabapentin or any of the test drugs.
  2. Any other form of non-diabetic distal symmetric polyneuropathy or any other pain condition that can impair the study endpoint (e.g. painful conditions where the intensity of pain is significantly more severe than the diabetic peripheral neuropathic pain).
  3. Concomitant treatment with medications for pain management that could not be discontinued.
  4. Concomitant treatment with potent inhibitors (e.g. ketoconazole, ritonavir, indinavir) or drugs known to prolong .
  5. Use of trazodone or gabapentin in the previous 3 months.
  6. Known history of previous non-responder to gabapentin treatment.
  7. Use of high dose morphine (e.g. > 120 mg/day) at the Screening Visit.
  8. abnormalities on physical examination, vital signs, elettrocardiogram, laboratory tests at Screening Visit that in the opinion of Investigator would compromise patient's participation in the study.
  9. Active foot ulcer or previous major limb amputation.
  10. Concurrent heart failure ≥ 4 class according to (NYHA) or myocardial infarction or angioplasty or by-pass graft procedures within the past 6 months.
  11. Patient with increased risk of Torsade de Pointes (e.g. family history of long QT syndrome) or QTcF value higher than 450 msec (male) and QTcF value higher than 470 msec (female) at Screening Visit.
  12. or cerebral vascular accident within the past 6 months.
  13. value \< 50 ml/min calculated with Modification of Diet in Renal Disease formula.
  14. Significant liver disease, defined as known active hepatitis or elevated liver enzymes over 3-fold the upper normal limit of laboratory normal ranges.
  15. Patient with latent or known hereditary problems of galactose intolerance or the Lapp lactase deficiency or glucose-galactose malabsorption.
  16. Positive urine drug screen for Central Nervous System active drugs (cocaine, opioids, amphetamines and cannabinoids) at Screening Visit.
  17. Positive present history of glaucoma.
  18. Hyperthyroidism, even if pharmacologically corrected.
  19. Significant mental disorders.
  20. Suicide risk score ≥ 2 on question 9 of the Beck Depression Inventory-II (BDI-II) at Screening visit or Visit 0.
  21. History of epilepsy or seizure events other than a single childhood febrile seizure.
  22. History of alcohol or psychoactive substance abuse or addiction.
  23. Use of neurological device (e.g. neurostimulation devices, etc).
  24. Women during pregnancy or lactation period.
  25. Inability to comply with the protocol requirements, instructions or study-related restrictions (e.g. uncooperative attitude, inability to return for study visits, improbability of completing the clinical study, etc).
  26. Subject involved in the conduct of the study (e.g. Investigator or his/her deputy, first grade relatives, pharmacist, assistant or other personnel, etc).
  27. Participation to an interventional clinical trial within 3 months prior to Screening Visit.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    trazodone/gabapentin 2.5/25 mg

    One capsule, three times a day, for 8 weeks. The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.

    Drug: trazodone/gabapentin 2.5/25 mg

  • Experimental
    trazodone/gabapentin 5/50 mg

    One capsule, three times a day, for 8 weeks.

    Drug: trazodone/gabapentin 5/50 mg

  • Experimental
    trazodone/gabapentin 10/100 mg

    One capsule, three times a day, for 8 weeks.

    Drug: trazodone/gabapentin 10/100

  • Placebo comparator
    placebo

    Two capsules, three times a day, for 8 weeks.

    Drug: Placebo oral capsule

  • Active comparator
    Gabapentin

    according to the following scheduling dosage regimen: * 100 mg (2 capsules) 3 times a day, from day 0 to day 6 (±1); * 300 mg (1 capsule) 3 times a day, from day 7 (±1) to day 13 (±1); * 400 mg (1 capsule) 3 times a day, from day 14 (±1) to day 20 (±1); * 300 mg (2 capsules) 3 times a day, from day 21 (±1) to day 55 (±2).

    Drug: Gabapentin

Interventions

  • Drugtrazodone/gabapentin 2.5/25 mg

    The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.

  • Drugtrazodone/gabapentin 5/50 mg

    The total daily doses administered will be trazodone 15 mg and gabapentin 150 mg.

  • Drugtrazodone/gabapentin 10/100

    The total daily doses administered will be trazodone 30 mg and gabapentin 300 mg.

  • The total daily doses administered will be: * 600 mg from day 0 to day 6 (±1) * 900 mg from day 7 (±1) to day 13 (±1) * 1200 mg from day 14 (±1) to day 20 (±1) * 1800 mg from day 21 (±1) to day 56 (±2)

    Also known as: Neurontin

  • DrugPlacebo oral capsule

    Two capsules, three times a day, for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change of the average daily pain score based on the 11-point Numeric Rating Scale (NRS).

    The NRS is based on a 11-point from 0 for \[no pain\] to 10 \[worst possible pain\].

    Time frame: Baseline - Day 56

Secondary outcomes

  1. Change of the average daily pain score based on the 11-point Numeric Rating Scale (NRS).

    The NRS is based on a 11-point from 0 for \[no pain\] to 10 \[worst possible pain\].

    Time frame: Baseline - Days 7, 14, 21, 28, 42

  2. Percentage of responder patients

    Responder patients are defined as ≥30% and ≥50% reduction from baseline of the average daily pain score based on the 11-point NRS.

    Time frame: Baseline - Day 56

  3. Change of the average daily pain score based on the 11-point NRS between gabapentin and placebo as assay sensitivity.

    The NRS is based on a 11-point from 0 for \[no pain\] to 10 \[worst possible pain\].

    Time frame: Baseline - Day 56

  4. Change of Brief Pain Inventory Short Form (BPI-SF) items 3, 4, 5, 6, 8 and 9 score.

    The BPI-SF is a numeric rating scale that assesses the severity of pain, its impact on daily functioning and other aspects of pain (e.g. location of pain, relief from medications). Items use a 0-10 numeric rating scale anchored at zero for "no pain" and 10 for "pain as bad as you can imagine" for Severity, and "does not interfere" to "completely interferes" for Interference.

    Time frame: Baseline - Days 28, 56

  5. Change of Neuropathic Pain Symptom Inventory (NPSI) total score.

    The NPSI is a self-questionnaire specifically designed to evaluate the different symptoms of neuropathic pain: It includes 10 descriptors plus two temporal items that allow discrimination and quantification of five distinct clinically relevant dimensions of neuropathic pain syndromes.

    Time frame: Baseline - Days 28, 56

  6. Change of Beck Depression Inventory - Second Edition (BDI-II)

    The BDI-II consists of 21 items to assess the intensity of depression in clinical and normal patients. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression and scored from 0 to 3.

    Time frame: Baseline - Days 28, 56

  7. Change of Hospital Anxiety and Depression Scale (HADS).

    The HADS is used to assess the level of anxiety and depression that a patient is experiencing. This is 14-item scale: seven related to the anxiety and seven to depression. Each item is scored from 0 to 3.

    Time frame: Baseline - Days 28, 56

  8. Change of Insomnia Severity Index (ISI).

    The ISI is a 7-item self-reported instrument measuring the patient's perception of his/her insomnia.Total score ranges from 0-28 and the following categorization is applicable: 0-7 = absence of insomnia; 8-14 = subthreshold insomnia; 15-21 = moderate insomnia; 22-28 = severe insomnia.

    Time frame: Baseline - Days 28, 56

  9. Change of Euroqol-5D-5L (EQ-5D-5L)

    The EQ-5D-5L consists of the EQ-5D descriptive system (five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression assessed as no problems, slight problems, moderate problems, severe problems and extreme problems) and the EQ visual analogue scale (where the patient self-rates his/her health on a vertical visual analogue scale from 'The best health you can imagine' to 'The worst health you can imagine').

    Time frame: Baseline - Days 28, 56

  10. Clinical Global Improvement or Change (CGI-C).

    CGI-C provides a global rating of patient's Improvement and scores range from "0 - not assessed" through to "7 - very much worse".

    Time frame: Baseline - Days 28, 56

  11. Frequency of adverse events

    Monitoring of the treatment related adverse events.

    Time frame: 65 days

07

Study locations

30 sites
  • Neurosanatio s.r.o.
    Litomyšl, 570 01, Czechia
  • Cerebrovaskulární poradna, s.r.o.
    Ostrava - Poruba, 70800, Czechia
  • Nemocnice Pardubického kraje a.s. Pardubická nemocnice Neurologická klinika
    Pardubice, 532 03, Czechia
  • Diabetologická ambulance Milan Kvapil s.r.o.
    Praha 4, 149 00, Czechia
  • Axon Clinical s.r.o
    Praha 5, 15000, Czechia
  • FORBELI s.r.o.
    Praha 6, 160 00, Czechia
  • Clintrial s.r.o.
    Praha, 100 00, Czechia
  • Fondation Hôtel Dieu Groupe SOS Service de Diabétologie
    Le Creusot, 71200, France
  • GHR MSA - Hôpital Emile Muller Service de Diabétologie-Endocrinologie-Nutrition
    Mulhouse, 68100, France
  • CHU de Nantes - Hôpital Guillaume-et-René-Laënnec Clinique d'Endocrinologie, maladies métaboliques et nutrition CIC Endocrino - Nutrition - UF 7015
    Nantes Cedex 144 093, France
  • Centre de Recherche Clinique G.H.M les Portes du Sud Departement d'Endocrinologie
    Venissieux, 69200, France
  • Centrum Badań Klinicznych PI-House
    Gdansk, 80-546, Poland
  • Silmedic Sp. z o.o.
    Katowice, 40-282, Poland
  • Pro Familia Altera Poradnia Wielospecjalistyczna
    Katowice, 40-648, Poland
  • Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne DIAB-ENDO-MET
    Kraków, 31-261, Poland
  • NZOZ Neuromed M. i M. Nastaj Sp. P.
    Lublin, 20-064, Poland
  • Instytut Medycyny Wsi im. Witolda Chodźki Klinika Diabetologii
    Lublin, 20-090, Poland
  • Centrum Medyczne HCP Sp. z o.o.
    Poznań, 61-485, Poland
  • RCMed Oddział Sochaczew
    Sochaczew, 96-500, Poland
  • Nasz Lekarz Przychodnie Medyczne
    Toruń, 87-100, Poland
  • Medycyna Kliniczna
    Warszawa, 00-874, Poland
  • Instytut Diabetologii
    Warszawa, 04-736, Poland
  • WroMedica I. Bielicka, A. Strzałkowska s.c.
    Wrocław, 51- 685, Poland
  • Centrum Badań Klinicznych Ośrodek Badań Wczesnej Fazy
    Wrocław, 51-162, Poland
  • Medical Innovation Development and Research Unit (MIDRU) Heartlands Hospital
    Birmingham, United Kingdom
  • Diabetes Centre Wythenshawe Hospital
    Manchester, United Kingdom
  • Manchester Clinical Research Facility Manchester Royal Infirmary
    Manchester, United Kingdom
  • Diabetes Centre George Eliot Hospital NHS Trust
    Nuneaton, United Kingdom
  • Lancashire Clinical Research Facility The Avondale Unit Royal Preston Hospital
    Preston, United Kingdom
  • Clinical Research Facility Royal Hallamshire Hospital
    Sheffield, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jun 2020, 18 months.

Of 25 phase 2 interventional studies under Diabetic Neuropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 35. This study's 18 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2018
First posted
Nov 21, 2018
StartActual
Nov 22, 2018
Primary completionActual
Jun 6, 2020
CompletionActual
Jun 6, 2020
Last update
May 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03749642
Collaborators
Chiltern International Inc.
Responsible party
Sponsor
First posted
Nov 21, 2018
Start date
Nov 22, 2018
Primary completion
Jun 6, 2020
Completion
Jun 6, 2020
Last update
May 27, 2021

Study contacts

Solomon Tesfaye, MD
principal investigator · Sheffield Teaching Hospitals NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion